Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16267261 | 1.00 | MAPK13 (0.37) | MAPK13MAPK12MAPK11MAPK14PRCP | |
| SCHEMBL19209573 | 0.86 | MAPK13 (0.40) | MAPK13MAPK12MAPK11MAPK14PRCP | |
| SCHEMBL18080872 | 0.86 | MAPK13 (0.40) | MAPK13MAPK12MAPK11MAPK14PRCP | |
| Hydrochloric Acid SCHEMBL18301377 | 0.85 | MAPK13 (0.39) | MAPK13MAPK12MAPK11MAPK14PRCP | |
| Hydrochloric Acid SCHEMBL18301378 | 0.85 | MAPK13 (0.39) | MAPK13MAPK12MAPK11MAPK14PRCP | |
| SCHEMBL15088062 | 0.84 | MAPK13 (0.41) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL18829568 | 0.79 | MAPK13 (0.40) | MAPK13MAPK12MAPK11MAPK14PRCP | |
| SCHEMBL19883563 | 0.77 | NPY5R (0.33) | — | |
| SCHEMBL15443862 | 0.77 | NPY5R (0.31) | — | |
| SCHEMBL21146105 | 0.77 | NPY5R (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2797911-B1 | HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-28 | — | — | EP | disclosed |
| US-9126986-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-08 | — | — | US | disclosed |
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2014-12-04 | — | — | US | disclosed |
| EP-2797911-A1 | HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS | Janssen R&D Ireland (IE) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013098313-A1 | HETERO-BICYCLIC DERIVATIVES AS HCV INHIBITORS | JANSSEN R&D IRELAND (IE) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | HAVCR2, ZC3HAV1, SUB1 | MAPK13 3677/4885MAPK12 3696/4885MAPK11 3853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.